Alan Skarbnik, MD

Articles

Dr. Skarbnik on the Optimization of CAR T-Cell Therapy Sequencing in MCL

April 22nd 2021

Alan P. Z. Skarbnik, MD, discusses the optimization of treatment sequencing with CAR T-cell therapy in mantle cell lymphoma.

Dr. Skarbnik on Current Treatment Strategies Making Waves in MCL

November 19th 2020

Alan P. Z. Skarbnik, MD, discusses treatment strategies for patients with mantle cell lymphoma.

Dr. Skarbnik on Selecting Between BTK Inhibitors in MCL

October 23rd 2020

Alan P. Z. Skarbnik, MD, discusses factors to consider in selecting between BTK inhibitors in mantle cell lymphoma.

Dr. Skarbnik on Treatment Considerations in CLL

October 22nd 2020

Alan P. Z. Skarbnik, MD, discusses treatment considerations in chronic lymphocytic leukemia.

Dr. Skarbnik on Frontline Treatment Considerations in CLL

October 20th 2020

Alan P. Z. Skarbnik, MD, discusses frontline treatment considerations in chronic lymphocytic leukemia.

Dr. Skarbnik on Future Combination Therapies With Tazemetostat in Follicular Lymphoma

September 29th 2020

Alan P. Z. Skarbnik, MD, discusses future combination therapies with tazemetostat in follicular lymphoma.

Dr. Skarbnik on the Approval of Tazemetostat in Relapsed/Refractory Follicular Lymphoma

September 28th 2020

Alan P. Z. Skarbnik, MD, highlights the approval of tazemetostat in relapsed/refractory follicular lymphoma.

Dr. Skarbnik on the Utility of PI3K Inhibitors in Follicular Lymphoma

September 25th 2020

Alan P. Z. Skarbnik, discusses ongoing research with PI3​K inhibitors in follicular lymphoma. 

Dr. Skarbnik on the Importance of Personalized Treatment for Follicular Lymphoma

September 19th 2020

Alan P. Z. Skarbnik, MD, discusses the importance of personalizing treatment for patients with follicular lymphoma.

Dr. Skarbnik on Active Surveillance in Follicular Lymphoma

August 22nd 2020

Alan P. Z. Skarbnik, MD, discusses the watch-and-wait approach in patients with follicular lymphoma.

Dr. Skarbnik Discusses the Changing Landscape of CLL

May 7th 2018

Alan Skarbnik, MD, staff physician, Department of Bone Marrow Transplantation and Department of Lymphoma, John Theurer Cancer Center, discusses the changing treatment landscape of chronic lymphocytic leukemia.

Dr. Skarbnik on the Role of Chemotherapy in CLL

March 30th 2018

Alan Skarbnik, MD, staff physician, Department of Bone Marrow Transplantation and Department of Lymphoma, John Theurer Cancer Center, discusses the use of chemotherapy in patients with chronic lymphocytic leukemia (CLL).

Dr. Skarbnik on Triplet Combination Strategies for Hematologic Malignancies

March 16th 2018

Alan Skarbnik, MD, staff physician, department of Bone Marrow Transplant, Department of Lymphoma, John Theurer Cancer Center, discusses triplet combinations in hematologic malignancies.

Dr. Skarbnik on Combination Strategies of Immunotherapy in Hematologic Malignancies

March 2nd 2018

Alan Skarbnik, MD, staff physician, department of Bone Marrow Transplant, Department of Lymphoma, John Theurer Cancer Center, discusses combination strategies with immunotherapy for patients with hematologic malignancies.

Dr. Skarbink on Unmet Needs for High-Risk Hematologic Malignancies

February 6th 2018

Alan Skarbnik, MD, staff physician, department of Bone Marrow Transplant, department of Lymphoma, John Theurer Cancer Center, discusses unmet needs for patients with high-risk hematologic malignancies.

Dr. Skarbnik on Impact of Checkpoint Inhibition Following ASCT

January 30th 2018

Alan Skarbnik, MD, staff physician, department of Bone Marrow Transplant, department of Lymphoma, John Theurer Cancer Center, discusses the preliminary safety and efficacy data for checkpoint inhibition with ipilimumab (Yervoy) and nivolumab (Opdivo) following autologous stem cell transplantation in high-risk hematologic malignancies.